Sugi Predict

Sugi Predict / Compounds / SCHEMBL2387673

SCHEMBL2387673

SCHEMBL2387673

CC(C)(C)OC(=O)N1CC(OCCOCc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.47
▸ WDR77 Q9BQA1 1/20 0.47
▸ LIPG Q9Y5X9 1/20 0.45
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ STS P08842 1/20 0.44
▸ NAMPT P43490 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RORC P51449 3/20 0.43
▸ GPR119 Q8TDV5 2/20 0.43
▸ KIT P10721 1/20 0.42
▸ FLT3 P36888 1/20 0.42
▸ TACR1 P25103 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ BACE2 Q9Y5Z0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28959331 0.93 L3MBTL1 (0.50) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL20129209 0.93 L3MBTL1 (0.47) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL20132906 0.92 L3MBTL1 (0.47) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL30763553 0.91 LIPG (0.43) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL22906672 0.91 L3MBTL1 (0.51) PRMT5WDR77JAK2JAK1STS
SCHEMBL9938446 0.89 PRMT5 (0.51) PRMT5WDR77JAK2JAK1STS
SCHEMBL21458596 0.88 STS (0.53) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL31618610 0.88 PRMT5 (0.49) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL22906856 0.87 STS (0.52) PRMT5WDR77LIPGJAK2JAK1
SCHEMBL21458929 0.87 STS (0.52) PRMT5WDR77LIPGJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149545-A1 HETEROARYLPHENYL ETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-07-17 — — WO disclosed
US-20240217947-A1 Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2024-07-04 — — US disclosed
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H BIOTECH INC. (KR) 2023-10-12 — — US disclosed
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H BIOTECH INC. (KR) 2023-10-12 — — US disclosed
CN-116490184-A Compounds for inhibiting EGFR mutant cancers and pharmaceutical uses thereof J2H生物科技有限公司 2023-07-25 — — CN disclosed
EP-4212522-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H Biotech Inc. (KR) 2023-07-19 — — EP disclosed
EP-4212522-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF J2H Biotech Inc. (KR) 2023-07-19 — — EP disclosed
WO-2023097189-A1 AMPK ACTIVATORS KALLYOPE, INC. (US) 2023-06-01 — — WO disclosed
WO-2023097187-A1 AMPK ACTIVATORS KALLYOPE, INC. (US) 2023-06-01 — — WO disclosed
WO-2023097189-A1 AMPK ACTIVATORS KALLYOPE, INC. (US) 2023-06-01 — — WO disclosed
EP-4058457-A2 NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS Ildong Pharmaceutical Co., Ltd. (KR) 2022-09-21 — — EP disclosed
CN-115038704-A Nitrogen oxide donating PDE-5 and/or PDE-6 inhibitor compounds 日东制药股份有限公司 2022-09-09 — — CN disclosed
US-20220153746-A1 NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-05-19 — — US disclosed
WO-2022096930-A2 NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-05-12 — — WO disclosed
WO-2021094830-A2 NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS ILDONG PHARMACEUTICAL CO., LTD. (KR) 2021-05-20 — — WO disclosed
US-8017611-B2 Pyridine and pyrazine derivatives -083 ASTRAZENECA AB (SE) 2011-09-13 — — US disclosed
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 — — EP disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 — — EP disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 — — US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217947-A1 Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof HDAC6, HDAC9, HDAC7 PRMT5 1023/4885WDR77 2784/4885LIPG 1971/4885
US-20230322723-A1 COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF EGFR, KRAS, ERBB2 PRMT5 392/4885WDR77 2245/4885LIPG 477/4885
US-20220153746-A1 NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS, AND USES THEREOF PDE6G, PRKG1, PDE6D PRMT5 97/4885WDR77 4752/4885LIPG 303/4885
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 MKI67, CCND3, CCND1 PRMT5 871/4885WDR77 1722/4885LIPG 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.